Cingulate Inc.
CINGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and. At a $74.2M market cap, Cingulate Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Market Cap
$74.2M
Beta
-0.89
P/E (TTM)
—
P/E (Fwd)
-5.80
EPS (TTM)
$-3.56
EPS (Fwd)
$-0.88
ROE
-198.7%
ROA
-66.9%
Cash
$28.4M
Total Debt
$6.3M
Free CF
-$12.8M
52W Change
33.9%
Annual Financials
Cash vs Debt
Where CING stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CING finished 7.54% below its 150-day moving average ($5.57) and 2.09% below its 200-day moving average ($5.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CING overbought or oversold?
At the September 3, 2026 close, CING's RSI(14) was 54.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $28.4M in cash and $6.3M in debt, CING maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$12.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -198.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CING's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CING has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CING.